0:000:00
<p><a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1743909/open_sms">Send us a text</a></p><p>Welcome back, Rounds Table Listeners! This week we have a solo episode with Dr. John Fralick, discussing a recently published trial of the GLP-1 receptor agonist semaglutide for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). Here we go!</p><ol><li><a href='https://www.nejm.org/doi/10.1056/NEJMoa2413258'>Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis</a> (0:00 – 6:33).</li></ol><p>The Good Stuff:</p><ul><li>Go Leafs go!</li></ul><p>Questions? Comments? Feedback? We’d love to hear from you! @roundstable @InternAtWork @MedicinePods</p>